Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
Click here to be directed to the Finch Therapeutics Group website. PRISM 3, a clinical trial in recurrent CDI is actively enrolling patients. For more information, please visit clinicaltrials.gov.
LEARN MORE
NEWS
10.23.2017
Finch Therapeutics and Crestovo Announce Merger to Form Finch Therapeutics Group, a Leading, Fully Integrated Microbiome Company
Merged entity includes a diverse pipeline of Full-Spectrum MicrobiotaTM and Rationally-Selected MicrobiotaTM products, an innovative discovery platform, large-scale manufacturing capabilities
FULL ARTICLE6.27.2017
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent Clostridium difficile Infection
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a Microbiome Therapy for the Prevention of Recurrent <em>Clostridium...
FULL ARTICLE
FULL-SPECTRUM MICROBIOTATM
At Crestovo, we are leveraging our industry-leading Full-Spectrum Microbiota™ (FSM™) platform to develop therapeutics that harness the human gut microbiome to restore diversity of healthy microorganisms. Through this approach, we are working to treat conditions with significant unmet medical need where patients are suffering from dysbiosis, including recurrent Clostridium difficile infection (CDI).
VISIT OUR PLATFORMJOIN OUR TEAM
Crestovo is looking for dynamic, driven individuals to join our team that is focused on treating serious diseases, pioneering breakthroughs in the biopharmaceutical industry and making a positive impact on patients’ lives. Ready to be part of a world-class team at the forefront of the microbiome movement?
CAREER OPPORTUNITIES